CXCL12 and B-cell chronic lymphocytic leukemia: Research has shown that NLCs from the blood of CLL patients can activate the p44/42 MAPK signaling pathway within CLL cells through the SDF-1α/CXCR4 pathway, thereby protecting CLL B cells from apoptosis and promoting their survival in vitro (73).